胶质与轴索损伤生物标志物在视网膜母细胞瘤颅内转移中的监测价值
Monitoring value of glial and axonal injury biomarkers in intracranial metastasis of retinoblastoma
摘要
目的:探讨胶质与轴索损伤生物标志物在视网膜母细胞瘤(RB)颅内转移监测中的应用价值。方法:采用回顾性病例对照研究,选取2025年1月1日至12月1日首都医科大学附属北京同仁医院收治的RB患儿40例[男22例,女18例,年龄36(12,51)个月],按颅内转移状态分为伴颅内转移组(20例)与无颅内转移组(20例)。采集空腹外周静脉血,采用化学发光法检测血清胶质纤维酸性蛋白(GFAP)、神经丝轻链(NfL)、S100β蛋白及血管内皮生长因子(VEGF)水平。采用受试者操作特征(ROC)曲线的曲线下面积(AUC)分析各标志物对RB颅内转移的诊断效能。结果:伴颅内转移组血清NfL水平高于无颅内转移组[4.66(3.40,17.93)ng/L 比1.10(1.00,2.18)ng/L,
P<0.001];伴颅内转移组血清GFAP水平亦高于无颅内转移组[141.40(113.85,189.62)ng/L比83.98(66.74,100.67)ng/L,
P=0.003];两组间血清S100β(
P=0.433)和VEGF(
P=0.675)水平差异均无统计学意义。ROC曲线结果显示,血清NfL诊断RB颅内转移的敏感度为95.0%,特异度为80.0%,AUC为0.931(95%
CI 0.835~0.995),最佳截断值为2.83 ng/L;血清GFAP的AUC为0.777(95%
CI 0.599~0.920),最佳截断值为116.10 ng/L,敏感度为75.0%,特异度为85.0%;S100β和VEGF的AUC分别为0.426和0.460,诊断价值有限。
结论:血清NfL与GFAP对RB颅内转移具有一定的诊断价值,其中NfL诊断效能较好,可为RB颅内转移的筛查提供血清学参考依据。
Objective:To investigate the clinical utility of glial and axonal injury biomarkers for monitoring retinoblastoma (RB) metastasis in the brain.Methods:A retrospective case-control study was conducted. Forty paediatric patients with retinoblastoma (22 males and 18 females aged 36 months on average, ranging from 12 to 51 months) admitted to Beijing Tongren Hospital, which is affiliated with Capital Medical University, between 1 January and 1 December 2025, were enrolled in the study and divided into two groups: one with intracranial metastasis (20 cases) and one without (20 cases). Fasting peripheral venous serum was collected and the levels of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), S100β protein and vascular endothelial growth factor (VEGF) were measured using chemiluminescence. The area under the carve(AUC) by the receiver operating characteristic (ROC) analysis was used for the discriminatory performance of each biomarker for intracranial metastases in retinoblastoma.Results:Serum NfL levels were higher in the group with intracranial metastases than in the group without [4.66 (3.40, 17.93) ng/L vs. 1.10 (1.00, 2.18) ng/L,
P<0.001]. Serum GFAP levels were also higher in the group with intracranial metastases [141.40 (113.85, 189.62) ng/L vs. 83.98 (66.74, 100.67) ng/L,
P=0.003]. There were no statistically significant differences in serum S100β levels (
P=0.433) or VEGF (
P=0.675) levels between the two groups. ROC curve analysis showed that serum NfL had a better diagnostic value for distinguishing intracranial metastases of RB: sensitivity was 95.0%, specificity was 80.0%, and the area under the curve (AUC) was 0.931(95%
CI 0.835-0.995), with an optimal cut-off value of 2.83 ng/L. The AUC for serum GFAP was 0.777 (95%
CI 0.599-0.920), with an optimal cut-off value of 116.10 ng/L (sensitivity was 75.0%, specificity was 85.0%). The AUC for S100β and VEGF were 0.426 and 0.460, respectively, indicating limited value.
Conclusion:Serum NfL and GFAP are useful for diagnosing intracranial metastases of RB, with NfL demonstrating a better diagnostic performance. They can be used as serological markers to screen for these metastases.
年,卷(期):
2026, 49(10)
在线出版日期:
2026年10月19日